Isis Books Kynamro Milestone; Seeks Partners For Other Pipeline Assets
This article was originally published in The Pink Sheet Daily
Executive Summary
The focus at Isis turns to the near-term prospects of an approval for the cholesterol drug Kynamro and to business development.